(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of 36.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Day One Biopharmaceuticals's revenue in 2026 is $158,182,000.On average, 11 Wall Street analysts forecast DAWN's revenue for 2026 to be $25,331,692,764, with the lowest DAWN revenue forecast at $23,013,692,578, and the highest DAWN revenue forecast at $27,375,954,069. On average, 10 Wall Street analysts forecast DAWN's revenue for 2027 to be $32,456,134,512, with the lowest DAWN revenue forecast at $28,122,796,375, and the highest DAWN revenue forecast at $37,474,336,341.
In 2028, DAWN is forecast to generate $42,009,104,976 in revenue, with the lowest revenue forecast at $33,275,285,202 and the highest revenue forecast at $51,539,349,948.